STOCK TITAN

United Therapeutics (UTHR) CFO sells 10,000 shares after exercising options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions. The sales occurred at weighted average prices within ranges described in the filing, including from $551.68 to $571.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, Edgemond directly holds 18,876 shares of United Therapeutics Common Stock.

Positive

  • None.

Negative

  • None.

Insights

CFO exercised options and sold shares under a pre‑set trading plan.

The filing shows CFO and Treasurer James Edgemond exercised options to acquire 10,000 shares at $135.42 per share, then sold the same number of shares in multiple open‑market trades at prices generally in the mid‑$500s. This is a classic exercise‑and‑sell pattern.

The footnote states the exercise and subsequent sales were made pursuant to a Rule 10b5‑1 trading plan entered on October 31, 2025, indicating the trades were pre‑scheduled rather than timed opportunistically. After these transactions, Edgemond holds 18,876 shares directly, so he retains a meaningful equity stake.

Because the transactions are compensation‑related, conducted under a pre‑arranged plan, and the CFO continues to hold shares, they are typically interpreted as routine liquidity management rather than a clear signal about the company’s prospects.

Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.61M)
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 --
Exercise Common Stock 10,000 $135.42 $1.35M
Sale Common Stock 40 $551.8638 $22K
Sale Common Stock 401 $553.9857 $222K
Sale Common Stock 778 $555.2198 $432K
Sale Common Stock 844 $556.1708 $469K
Sale Common Stock 977 $557.0456 $544K
Sale Common Stock 720 $558.1072 $402K
Sale Common Stock 240 $559.028 $134K
Sale Common Stock 72 $560.3911 $40K
Sale Common Stock 571 $561.7471 $321K
Sale Common Stock 555 $562.9975 $312K
Sale Common Stock 896 $563.8634 $505K
Sale Common Stock 2,201 $564.8194 $1.24M
Sale Common Stock 742 $565.9912 $420K
Sale Common Stock 323 $566.8191 $183K
Sale Common Stock 400 $567.95 $227K
Sale Common Stock 120 $569.7467 $68K
Sale Common Stock 120 $571.6533 $69K
Holdings After Transaction: Stock Option — 122,500 shares (Direct); Common Stock — 28,876 shares (Direct)
Footnotes (1)
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $561.24 to $562.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $562.40 to $563.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.43 to $564.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.44 to $565.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.50 to $566.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $566.53 to $567.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $567.64 to $568.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $569.14 to $570.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.53 to $571.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $551.68 to $552.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $553.54 to $554.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $554.58 to $555.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $555.62 to $556.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $556.62 to $557.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $557.75 to $558.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $558.79 to $559.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $560.00 to $560.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Options exercised 10,000 shares Stock options converted to Common Stock on April 2, 2026
Option exercise price $135.42/share Exercise price for 10,000 Stock Options
Shares sold 10,000 shares Total Common Stock sold across 17 open-market trades
Sale price range example $551.68–$552.02 One disclosed range of weighted average sale prices
Highest disclosed price range $571.53–$571.72 Upper end of reported multiple-trade price ranges
Shares held after transactions 18,876 shares Direct Common Stock ownership following April 2, 2026 trades
Rule 10b5-1 plan date October 31, 2025 Date CFO entered trading plan governing these transactions
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action: "open-market sale" in multiple non-derivative transactions"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/02/2026M(1)10,000A$135.4228,876D
Common Stock04/02/2026S(1)40D$551.8638(2)28,836D
Common Stock04/02/2026S(1)401D$553.9857(3)28,435D
Common Stock04/02/2026S(1)778D$555.2198(4)27,657D
Common Stock04/02/2026S(1)844D$556.1708(5)26,813D
Common Stock04/02/2026S(1)977D$557.0456(6)25,836D
Common Stock04/02/2026S(1)720D$558.1072(7)25,116D
Common Stock04/02/2026S(1)240D$559.028(8)24,876D
Common Stock04/02/2026S(1)72D$560.3911(9)24,804D
Common Stock04/02/2026S(1)571D$561.7471(10)24,233D
Common Stock04/02/2026S(1)555D$562.9975(11)23,678D
Common Stock04/02/2026S(1)896D$563.8634(12)22,782D
Common Stock04/02/2026S(1)2,201D$564.8194(13)20,581D
Common Stock04/02/2026S(1)742D$565.9912(14)19,839D
Common Stock04/02/2026S(1)323D$566.8191(15)19,516D
Common Stock04/02/2026S(1)400D$567.95(16)19,116D
Common Stock04/02/2026S(1)120D$569.7467(17)18,996D
Common Stock04/02/2026S(1)120D$571.6533(18)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$135.4204/02/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.00122,500D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $551.68 to $552.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $553.54 to $554.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $554.58 to $555.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $555.62 to $556.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $556.62 to $557.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $557.75 to $558.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $558.79 to $559.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $560.00 to $560.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $561.24 to $562.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $562.40 to $563.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
12. This transaction was executed in multiple trades at prices ranging from $563.43 to $564.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
13. This transaction was executed in multiple trades at prices ranging from $564.44 to $565.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
14. This transaction was executed in multiple trades at prices ranging from $565.50 to $566.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
15. This transaction was executed in multiple trades at prices ranging from $566.53 to $567.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
16. This transaction was executed in multiple trades at prices ranging from $567.64 to $568.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
17. This transaction was executed in multiple trades at prices ranging from $569.14 to $570.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
18. This transaction was executed in multiple trades at prices ranging from $571.53 to $571.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond do in this Form 4 filing?

United Therapeutics CFO James Edgemond exercised stock options for 10,000 shares and sold 10,000 shares of Common Stock. The transactions were executed in multiple open‑market trades and carried out under a pre‑arranged Rule 10b5‑1 trading plan disclosed in the filing.

How many United Therapeutics (UTHR) shares did the CFO sell and at what prices?

The CFO sold 10,000 shares of United Therapeutics Common Stock in 17 separate open‑market transactions. Reported weighted average prices fall within several disclosed ranges, including from $551.68 to $571.72 per share, with each range representing multiple individual trades aggregated in the filing.

What stock options did the United Therapeutics (UTHR) CFO exercise in this Form 4?

James Edgemond exercised stock options covering 10,000 shares of United Therapeutics Common Stock. The options had an exercise price of $135.42 per share and an expiration date of March 15, 2027, converting derivative holdings into directly owned common shares before the subsequent sales.

How many United Therapeutics (UTHR) shares does the CFO hold after these transactions?

After completing the option exercise and related share sales, the CFO directly holds 18,876 shares of United Therapeutics Common Stock. This post‑transaction balance is reported in the filing’s ownership columns and reflects his remaining direct equity stake following the disclosed activity.

Were the United Therapeutics (UTHR) CFO’s trades part of a Rule 10b5-1 plan?

Yes. A footnote explains that the option exercise and subsequent sale of shares were conducted under a Rule 10b5‑1 trading plan entered into on October 31, 2025. Such plans pre‑schedule trades, reducing the significance of trade timing as an indicator of insider sentiment.

What is the overall direction of the United Therapeutics (UTHR) CFO’s Form 4 transactions?

The filing combines an option exercise to acquire 10,000 shares with open‑market sales totaling 10,000 shares, resulting in a net sale of shares. However, because the trades were made under a Rule 10b5‑1 plan, they appear as planned liquidity management rather than discretionary market timing.